Nephromics (U.S. royalty obligation and worldwide diagnostics assets) Overview

  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • Asset Purch.
  • Financing Rounds
  • 1

Nephromics (U.S. royalty obligation and worldwide diagnostics assets) General Information

Description

U.S. royalty obligation and rights of worldwide diagnostics assets of Nephromics. The license is for tests related to the detection, monitoring and risk assessment of preeclampsia, a leading cause of maternal death.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Other Industries
Other Business Products and Services
Acquirer
Beckman Coulter
Primary Office
  • Chestnut Hill, MA
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Nephromics (U.S. royalty obligation and worldwide diagnostics assets) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Nephromics (U.S. royalty obligation and worldwide diagnostics assets)‘s full profile, request access.

Request a free trial

Nephromics (U.S. royalty obligation and worldwide diagnostics assets) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Nephromics (U.S. royalty obligation and worldwide diagnostics assets)‘s full profile, request access.

Request a free trial